BioNTech (BNTX) PT Lowered to $101 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $90.43 +4.04%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
UBS analyst Andrew Ang lowered the price target on BioNTech (NASDAQ: BNTX) to $101.00 (from $110.00) while maintaining a Neutral rating.
You May Also Be Interested In
- BioNTech (BNTX) PT Lowered to $106 at Morgan Stanley
- BioNTech SE (BNTX) Tops Q3 EPS by 98c; offers guidance
- BioNTech (BNTX) PT Lowered to $108 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
